Mibefradil

From Wikipedia, the free encyclopedia
Mibefradil
Systematic (IUPAC) name
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a607007
Legal status Withdrawn from market
Routes Oral
Identifiers
CAS number 116644-53-2 YesY
ATC code C08CX01
PubChem CID 60662
DrugBank DB01388
UNII 27B90X776A N
KEGG D08217 YesY
ChEMBL CHEMBL45816 N
Chemical data
Formula C29H38FN3O3 
Mol. mass 495.63 g/mol
 N (what is this?)  (verify)

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.

It is nonselective.[1]

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market,[2] due to the potential for drug interactions, some of them serious, which may occur when it is taken together with some other medications.

References



This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.